(Stroke. 1999;30:1561-1565.)
© 1999 American Heart Association, Inc.
Original Contributions |
Elevated Anticardiolipin Antibody Titer Is a Stroke Risk Factor in a Multiethnic Population Independent of Isotype or Degree of Positivity
From the Departments of Neurology (S.T., J.W., D.R.H.), Medicine (J.H.R., X-X.W., M.E.G.), and Community Medicine (J.H.G.), Mount Sinai School of Medicine, New York, NY.
Correspondence to Stanley Tuhrim, MD, Department of Neurology, One Gustave L. Levy Place, Box 1137, New York, NY 10029. E-mail s tuhrim{at}mssm.edutuhrim@mssm.edu
Background and Purpose—Previous studies have produced conflicting results regarding the putative association between anticardiolipin antibodies (aCL) and infarction in the general stroke population. These inconsistencies may be a function of sample size and methodological differences among the studies. The purpose of the present study, the largest case-control study of this issue to date, was to assess aCL status as an independent risk factor for ischemic stroke in a multiethnic, urban population.
Methods—We obtained aCL titers in 524 hospitalized acute stroke
patients and 1020 community controls enrolled in the Minorities Risk
Factors and Stroke Study. The results were interpreted as
negative (
22.9 IgG phospholipid [GPL] or 10.9 IgM phospholipid
[MPL] units), low positive (22.9 to 30.0 GPL or 10.9 to 15.0 MPL
units), or high positive (>30.0 GPL or 15.0 MPL units). Odds ratios
(ORs) were adjusted for age, sex, race/ethnicity, history of diabetes,
hypertension, atrial fibrillation, coronary artery disease, and
current cigarette smoking.
Results—A positive aCL titer was present in 11% (111/1020) of controls and 34% (180/524) of cases. The adjusted OR for any positive aCL titer was 4.0 (95% CI, 3.0 to 5.5). For any positive IgG aCL titer this value was 3.9 (95% CI, 2.8 to 5.5), and for any positive IgM aCL titer it was 3.4 (95% CI, 2.1 to 5.5). There were no significant differences in ORs associated with high- or low-positive IgG or IgM aCL titers.
Conclusions—In the largest study of its kind to date, aCL antibodies were demonstrated to be independent stroke risk factors across the 3 ethnic groups studied, conferring a 4-fold increased risk of ischemic stroke. IgG and for the first time IgM aCL were each shown to be associated with increased stroke risk. The prevalence of these antibodies and the stroke risk associated appear greater than previously reported.
Key Words: antibodies, anticardiolipin • antibodies, antiphospholipid • risk factors • stroke, ischemic
This article has been cited by other articles:
 |
|
 |
|
  K. Rajamani, S. Chaturvedi, Z. Jin, S. Homma, R. L. Brey, B. C. Tilley, R. L. Sacco, J.L.P. Thompson, J.P. Mohr, S. R. Levine, et al. Patent Foramen Ovale, Cardiac Valve Thickening, and Antiphospholipid Antibodies as Risk Factors for Subsequent Vascular Events: The PICSS-APASS Study Stroke, July 1, 2009; 40(7): 2337 - 2342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Wei Hsi Chen, Hung Sheng Lin, Yi Fen Kao, Min Yu Lan, and Jia Shou Liu Hyperhomocysteinemia Relates to the Subtype of Antiphospholipid Antibodies in Non-SLE Patients Clinical and Applied Thrombosis/Hemostasis, October 1, 2007; 13(4): 398 - 403. [Abstract] [PDF]
|
|
|
|
 |
|
 J. H. Rand The Antiphospholipid Syndrome Hematology, January 1, 2007; 2007(1): 136 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-H. Chen, C.-C. Lui, C.-J. Chen, and J.-S. Liu An Increase of Anticardiolipin Antibody in Association with Stroke and Chronic Chemical Exposure Clinical and Applied Thrombosis/Hemostasis, April 1, 2006; 12(2): 231 - 235. [Abstract] [PDF]
|
|
|
|
|
|
W. H. Chen, Y.-F. Kao, M.-Y. Lan, Y.-Y. Chang, S.-S. Chen, and J.-S. Liu The Increase of Blood Anticardiolipin Antibody Depends on the Underlying Etiology in Cerebral Ischemia Clinical and Applied Thrombosis/Hemostasis, January 1, 2006; 12(1): 69 - 76. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Kahles, M. Humpich, H. Steinmetz, M. Sitzer, and E. Lindhoff-Last Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke Rheumatology, September 1, 2005; 44(9): 1161 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Chen, Y.-F. Kao, M.-Y. Lan, Y.-Y. Chang, S.-S. Chen, and J.-S. Liu The Increase of Blood Anticardiolipin Antibody Depends on the Underlying Etiology in Cerebral Ischemia Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 203 - 210. [Abstract] [PDF]
|
|
|
|
|
|
S. Ferreira, D. P. D'Cruz, and G. R. V. Hughes Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology, April 1, 2005; 44(4): 434 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J G Ray, M M Mamdani, and W H Geerts Giant cell arteritis and cardiovascular disease in older adults Heart, March 1, 2005; 91(3): 324 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 89 - 126. [Abstract] [PDF]
|
|
|
|
|
|
V. Janardhan, P. A. Wolf, C. S. Kase, J. M. Massaro, R. B. D'Agostino, C. Franzblau, and P. W.F. Wilson Anticardiolipin Antibodies and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Cohort and Offspring Study Stroke, March 1, 2004; 35(3): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 APASS Investigators Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke JAMA, February 4, 2004; 291(5): 576 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lanthier, F. J. Kirkham, L. G. Mitchell, R. M. Laxer, E. Atenafu, C. Male, M. Prengler, T. Domi, A. K.C. Chan, R. Liesner, et al. Increased anticardiolipin antibody IgG titers do not predict recurrent stroke or TIA in children Neurology, January 27, 2004; 62(2): 194 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schattner and M. H. Liang The Cardiovascular Burden of Lupus: A Complex Challenge Arch Intern Med, July 14, 2003; 163(13): 1507 - 1510. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Galli, D. Luciani, G. Bertolini, and T. Barbui Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature Blood, March 1, 2003; 101(5): 1827 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sanna, M. L. Bertolaccini, M. J. Cuadrado, M. A. Khamashta, and G. R. V. Hughes Central nervous system involvement in the antiphospholipid (Hughes) syndrome Rheumatology, February 1, 2003; 42(2): 200 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin, W. C. Aird, and J. H. Rand Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome Hematology, January 1, 2003; 2003(1): 497 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Brey, C. L. Stallworth, D. L. McGlasson, M. A. Wozniak, R. J. Wityk, B. J. Stern, M. A. Sloan, R. Sherwin, T. R. Price, R. F. Macko, et al. Antiphospholipid Antibodies and Stroke in Young Women * Editorial Comment Stroke, October 1, 2002; 33(10): 2396 - 2401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Bushnell, Z. Siddiqi, and L. B. Goldstein Improving patient selection for coagulopathy testing in the setting of acute ischemic stroke Neurology, October 9, 2001; 57(7): 1333 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Brey, R. D. Abbott, J. D. Curb, D. S. Sharp, G. W. Ross, C. L. Stallworth, and S. J. Kittner {beta}2-Glycoprotein 1-Dependent Anticardiolipin Antibodies and Risk of Ischemic Stroke and Myocardial Infarction: The Honolulu Heart Program Stroke, August 1, 2001; 32(8): 1701 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-H. Luong, J. H. Rand, X.-X. Wu, J. H. Godbold, M. Gascon-Lema, and S. Tuhrim Seasonal Distribution of Antiphospholipid Antibodies Stroke, August 1, 2001; 32(8): 1707 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al. Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Circulation, January 2, 2001; 103(1): 163 - 182. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al. Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Stroke, January 1, 2001; 32(1): 280 - 299. [Full Text] [PDF]
|
|
|
|
|
|
B. G. Macik, J. H. Rand, and B. A. Konkle Thrombophilia: What's a Practitioner to Do? Hematology, January 1, 2001; 2001(1): 322 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Bushnell and L. B. Goldstein Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke Stroke, December 1, 2000; 31(12): 3067 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ahmed, B. Stegmayr, J. Trifunovic, L. Weinehall, G. Hallmans, and A. K. Lefvert Anticardiolipin Antibodies Are Not an Independent Risk Factor for Stroke : An Incident Case-Referent Study Nested Within the MONICA and Vasterbotten Cohort Project Stroke, June 1, 2000; 31(6): 1289 - 1293. [Abstract] [Full Text] [PDF]
|
|